Minerva Neurosciences (Minerva Neurosciences) Momentum Rank : 6 (As of Apr. 30, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Momentum Rank?

Minerva Neurosciences has the Momentum Rank of 6.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Minerva Neurosciences's Momentum Rank

For the Biotechnology subindustry, Minerva Neurosciences's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Momentum Rank falls into.

Minerva Neurosciences Momentum Rank Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Neurosciences (Minerva Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

4MNA:Germany 4MNA:Germany

Address

1500 District Avenue, Burlington, MA, USA, 01803

Website

https://www.minervaneurosciences.com

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Executives

Ag Boehringer	10 percent owner	BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh	10 percent owner	200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer	officer: EVP and Head of R&D	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race	officer: EVP and CFO	C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm	officer: Chief Accounting Officer	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly	officer: Chief Business Officer	C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell	officer: President	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle	director
Hans Peter Hasler	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd	10 percent owner	5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd	10 percent owner	44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG